c-Met-IN-22

c-Met-IN-22

• UNSPSC Description: c-Met-IN-22 (compound 51am) is an orally active inhibitor against c-Met with an IC50 value of 2.54 nM. c-Met-IN-22 has antiproliferative and antitumor activities. c-Met-IN-22 induces cell apoptosis[1].
• Target Antigen: Apoptosis; c-Met/HGFR
• Type: Reference compound
• Related Pathways: Apoptosis;Protein Tyrosine Kinase/RTK
• Applications: Cancer-Kinase/protease
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/c-met-in-22.html
• Solubility: 10 mM in DMSO
• Smiles: O=C(C1=NC(C2=CC=C(F)C(Cl)=C2)=CS1)NC3=CC=C(OC4=C(Cl)C(Cl)=NC=C4)C(F)=C3
• Molecular Weight: 512.74
• References & Citations: [1]Xiang Nan,et al. Design, synthesis, and biological evaluation of thiazole/thiadiazole carboxamide scaffold-based derivatives as potential c-Met kinase inhibitors for cancer treatment. J Enzyme Inhib Med Chem. 2023 Dec;38
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported